Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017)
Biomarin Pharmaceutical (BMRN) posted Current Deferred Revenue of $17.4 million for Q3 2017, up 1669.54% on a QoQ basis from $985000.0 in Q4 2016.
Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017) Analysis & Trends
Biomarin Pharmaceutical's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $17.4 million for Q3 2017.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $17.4 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $17.4 million (changed N/A YoY) and the FY2016 annual result came in at $985000.0, changed N/A from the prior year.
- Current Deferred Revenue was $17.4 million for Q3 2017 at Biomarin Pharmaceutical, up from $985000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $17.4 million in Q3 2017 and bottomed at $985000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 17.43 Mn |
| Dec 31, 2016 | 985,000.00 |
| Sep 30, 2012 | 1.08 Mn |
| Jun 30, 2012 | 1.11 Mn |
| Dec 31, 2011 | 342,000.00 |
| Dec 31, 2009 | 86,000.00 |